Informatie:
Fout:
ID
13647
Beschrijving
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial; ODM derived from: https://clinicaltrials.gov/show/NCT01347970
Link
https://clinicaltrials.gov/show/NCT01347970
Trefwoorden
Versies (1)
- 22-02-16 22-02-16 -
Geüploaded op
22 februari 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Cancer Survivor NCT01347970
Eligibility Cancer Survivor NCT01347970
- StudyEvent: Eligibility
Similar models
Eligibility Cancer Survivor NCT01347970
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
diagnosis cancer; age
Item
cancer diagnosis prior to 22 years of age, irrespective of current age
boolean
C0011900 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0006826 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
dose anthracycline; dexrazoxane
Item
lifetime cumulative anthracycline dose: >= 300 mg/m^2 without the protection of dexrazoxane (zinecard) therapy
boolean
C3174092 (UMLS CUI [1,1])
C0282564 (UMLS CUI [1,2])
C0086444 (UMLS CUI [2])
C0282564 (UMLS CUI [1,2])
C0086444 (UMLS CUI [2])
cancer treatment
Item
time from completion of cancer treatment to study entry: >= 2 years
boolean
C0920425 (UMLS CUI [1])
treatment cardiomyopathy; treatment congestive heart failure
Item
receiving treatment for cardiomyopathy or congestive heart failure
boolean
C0087111 (UMLS CUI [1,1])
C0878544 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018802 (UMLS CUI [2,2])
C0878544 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018802 (UMLS CUI [2,2])
ejection fraction
Item
resting ejection fraction < 50% or fractional shortening < 25%
boolean
C0489482 (UMLS CUI [1])
valvular disease; Ventricular Outflow Obstruction
Item
uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular outflow obstruction
boolean
C0018824 (UMLS CUI [1])
C0042512 (UMLS CUI [2])
C0042512 (UMLS CUI [2])
systolic blood pressure; hemoglobin
Item
low resting systolic blood pressure: < 90 mm hemoglobin (hg)
boolean
C0871470 (UMLS CUI [1])
C0019046 (UMLS CUI [2])
C0019046 (UMLS CUI [2])
bradycardia; heart rate
Item
bradycardia: heart rate < 50 beats per minute (bpm)
boolean
C0428977 (UMLS CUI [1])
C0018810 (UMLS CUI [2])
C0018810 (UMLS CUI [2])
ventricular dysrhythmias; sick sinus syndrome
Item
sustained or symptomatic ventricular dysrhythmias uncontrolled with drug therapy or implantable device; significant conduction defects (i.e.: second or third degree atrio-ventricular block or sick sinus syndrome)
boolean
C0085612 (UMLS CUI [1])
C0037052 (UMLS CUI [2])
C0037052 (UMLS CUI [2])
obstructive pulmonary disease
Item
history or current clinical evidence of moderate -to-severe obstructive pulmonary disease or reactive airway diseases (i.e.: asthma) requiring therapy
boolean
C0600260 (UMLS CUI [1])
Aspartate aminotransferase/Alanine aminotransferase; Gastrointestinal dysfunction
Item
significant hepatic (serum aspartate aminotransferase [ast] and/or alanine aminotransferase [alt] > 3 time upper limit of normal institutional normal), gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications
boolean
C0364051 (UMLS CUI [1])
C0679407 (UMLS CUI [2])
C0679407 (UMLS CUI [2])
endocrine disorders; primary aldosteronism
Item
endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism not controlled with medication, or insulin dependent diabetes mellitus
boolean
C0014130 (UMLS CUI [1])
C1384514 (UMLS CUI [2])
C1384514 (UMLS CUI [2])
Contraception status
Item
females of child bearing potential who are pregnant, lactating, or sexually active and not taking adequate contraceptive precautions (i.e.: intrauterine device [iud] or oral contraceptives for 3 months prior to entry into the study)
boolean
C0420837 (UMLS CUI [1])
hypersensitivity beta-blockers
Item
history of drug sensitivity or allergic reaction to alpha- or beta-blockers
boolean
C0020517 (UMLS CUI [1,1])
C0001645 (UMLS CUI [1,2])
C0001645 (UMLS CUI [1,2])
anemia; hematocrit
Item
anemia (hematocrit < 28%)
boolean
C0002871 (UMLS CUI [1])
C0018935 (UMLS CUI [2])
C0018935 (UMLS CUI [2])
investigational drug beta adrenergic blockers
Item
use of an investigational drug or beta adrenergic blockers, including metoprolol, sotalol, within 30 days of randomization
boolean
C0013230 (UMLS CUI [1,1])
C0001645 (UMLS CUI [1,2])
C0001645 (UMLS CUI [1,2])
Cytochrome P-450 CYP2D6
Item
use of select cytochrome p450 2d6 (cyp2d6) inhibitor medications
boolean
C0057223 (UMLS CUI [1])
pills
Item
inability to swallow pills
boolean
C0994475 (UMLS CUI [1])
compliance
Item
unwillingness or inability to cooperate, or, for the parents or guardians of minors, to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation with the study
boolean
C1321605 (UMLS CUI [1])
medication blood pressure
Item
use of any other blood pressure lowering medication for treatment of hypertension, within 30 days of randomization
boolean
C0013227 (UMLS CUI [1,1])
C0005823 (UMLS CUI [1,2])
C0005823 (UMLS CUI [1,2])
Geen commentaren